^
    Back
    Association details:
    Biomarker:TP53 mutation
    Cancer:Leiomyosarcoma
    Drug:dacarbazine (DNA synthesis inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    AACR 2020
    Title:

    Potential molecular biomarkers of response to eribulin in patients with leiomyosarcoma

    Published date:
    05/15/2020
    Excerpt:
    ATRX andTP53 mutations were not linked with clinical benefit/response to DTIC.